Bristol Myers scraps gene therapy deal with uniQure for cardiovascular diseases
Bristol Myers Squibb is hitting the exit on a collaboration with a gene therapy biotech.
The Big Pharma company will no longer partner with uniQure …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
